Trump Executive Order Accelerates Psychedelic Drug Approvals, Boosting Clearmind’s Veteran Mental Health Push

Event summary

  • President Trump’s April 18, 2026 Executive Order directs the FDA to prioritize psychedelic drug reviews for serious mental illness.
  • Clearmind’s MEAI compound was named in bipartisan U.S. legislation (H.R. 7091) in February 2026, potentially enabling VA-supported trials.
  • Company is advancing Phase I/IIa clinical trials of CMND-100 for alcohol use disorder at Yale and Johns Hopkins.
  • Clearmind holds 31 granted patents across 19 patent families.

The big picture

President Trump’s Executive Order marks a significant regulatory shift for psychedelic therapies, aligning with bipartisan legislative efforts to expand veteran access. Clearmind stands to benefit from streamlined FDA reviews and potential VA-backed trials, accelerating its mission to commercialize non-hallucinogenic neuroplastogen treatments for alcohol use disorder.

What we're watching

Regulatory Tailwinds
How the FDA’s accelerated review process will impact Clearmind’s CMND-100 approval timeline.
Legislative Momentum
Whether H.R. 7091 passes and enables VA-supported trials for alcohol use disorder treatments.
Clinical Execution
The pace at which Clearmind can advance its Phase I/IIa trials while expanding its patent portfolio.